Health Care Cost

Experts examined oncology care innovation, access gaps to CAR T-cell therapy, advances in myeloma care, and partnerships in value-based care.

Advanced therapies are pressuring reimbursement and necessitating real-world durability data and new payment models, said Fran Gregory, PharmD.

Specialty pharmacies play a critical role in connecting patients with assistance programs to combat growing financial complexities.

At AXS26, leaders shared the hard-won organizational, strategic, and operational lessons from rounds 1, 2, and 3 of the Medicare Drug Price Negotiation Program.

Lekan Ajayi, PharmD, explains how remote therapy monitoring keeps patients with cancer on track with their care and reduces emergency visits.

Based on their findings, the 2 experts suggested that tiered benefit design may already strongly influence consumer choices.

As pricing reforms like Most Favored Nation reshape global drug launches, patients may ultimately pay the highest price, said Dee Chaudhary of Clarivate.

Drug pricing transparency and easy discounts cut abandoned prescriptions, as federal policies put pressure on pharma, says Laura Jensen of GoodRx.

Justin Favaro, MD, discusses independent oncology models, ACA challenges, and strategies to reduce health care costs at IVBM Charlotte 2026.

House lawmakers questioned hospital CEOs over rising health care costs, consolidation, opaque billing, Medicaid cuts, and site neutrality.

The entire commercial logic of the pharmaceutical industry’s patient engagement model is built for a moment that no longer exists, according to Chris Moose.

Policy and market access experts break down the compounding forces reshaping drug pricing, PBM regulation, and manufacturer strategy heading into the 2026 midterms.

OCM showed no increased likelihood of starting systemic therapy in patients with newly diagnosed cancers, despite gains in poor-prognosis cases.

New reports spotlight inequities—from Black maternal mortality to 988’s youth impact—as well as rising cancer risk and gaps in food aid.

Pediatric care deserts push Medicaid families into costly ED visits; learn how primary care access gaps fuel chronic issues and spending.

The 2018 permanent authorization of dual-eligible special needs plans marked a significant long-term commitment by policy makers and coincided with substantial growth in plan offerings and enrollment.

This article presents a microcosting analysis of resources needed for the implementation and sustainment of the Massachusetts model evaluated in the PROUD trial.

Black Maternal Health Week spotlights disparities, Medicaid postpartum coverage gains, and ongoing policy efforts to reduce maternal mortality.

Receipt of an insurer-provided grocery benefit was associated with decreased rates of diabetes with complications and increased medication adherence among a population with diabetes.

Experts from AMCP emphasize the importance of drug-adjacent early detection tests and screening ability to improve patient outcomes.

Experts from AMCP discuss the real-world evidence on GLP-1 usage and health care spending.

Daryl Pritchard, PhD, discusses the challenges to implementing biomarker testing that would advance precision medicine and improve patient outcomes in oncology.

Quality metrics for screening tests must evolve to mandate diagnostic resolution, ensuring financial and clinical incentives prioritize the complete screening continuum over initial test uptake.

Patty Taddei-Allen, PharmD, MBA, examines how co-pay accumulators, maximizers, and AFPs shift costs, impact rebates, and create access challenges for patients.

At AMCP 2026, Adam Colborn, JD, warns the Alternatives to PAIN Act may expand access but risk destabilizing Medicare Part D and limiting plan participation.